Evidence map›Paper›PMID 29808028›Full record

ArticleNature genetics2018

Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression.

Yajia Zhang, Sethuramasundaram Pitchiaya, Marcin Cieślik, Yashar S Niknafs, Jean C-Y Tien, Yasuyuki Hosono, Matthew K Iyer, Sahr Yazdani, Shruthi Subramaniam, Sudhanshu K Shukla and 27 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed, 3 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

137 citing papers in PubMed, 3 syntheses or guidelines pooled it, 237 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. A Spatiotemporal Atlas of the Androgen Receptor Proximal Interactome.bioRxiv : the preprint server for biology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. A circRNA-mRNA pairing mechanism regulates tumor growth and endocrine therapy resistance in ER-positive breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  20. Review

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 8 institutions in 4 countries.

Yajia ZhangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Sethuramasundaram PitchiayaMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Marcin CieślikMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Yashar S NiknafsMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Jean C-Y TienMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Yasuyuki HosonoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Matthew K IyerMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Sahr YazdaniMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Shruthi SubramaniamMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Sudhanshu K ShuklaMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Xia JiangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Lisha WangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Tzu-Ying LiuDepartment of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
Michael UhlDepartment of Computer Science and Centre for Biological Signaling Studies (BIOSS), University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-9563-4991
Alexander R GawronskiSchool of Computing Science, Simon Fraser University, Burnaby, British Columbia, Canada.
Yuanyuan QiaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Lanbo XiaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Saravana M DhanasekaranMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Kristin M JucketteMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Lakshmi P KunjuMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Xuhong CaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Utsav PatelNew Jersey Medical School, Rutgers University, Newark, NJ, USA.
Mona BatishNew Jersey Medical School, Rutgers University, Newark, NJ, USA.
Girish C ShuklaDepartment of Biological, Geological and Environmental Sciences, Center for Gene Regulation in Health and Disease, Cleveland State Univesity, Cleveland, OH, USA.
Michelle T PaulsenRogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Mats LjungmanRogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Hui JiangDepartment of Biostatistics, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0003-2718-9811
Rohit MehraDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Rolf BackofenDepartment of Computer Science and Centre for Biological Signaling Studies (BIOSS), University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0001-8231-3323
Cenk S SahinalpSchool of Informatics and Computing, Indiana University, Bloomington, IN, USA.
Susan M FreierIonis Pharmaceuticals, Carlsbad, CA, USA.
Andrew T WattIonis Pharmaceuticals, Carlsbad, CA, USA.
Shuling GuoIonis Pharmaceuticals, Carlsbad, CA, USA.
John T WeiDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Felix Y FengMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Rohit MalikMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA. arul@umich.edu.ORCID http://orcid.org/0000-0001-9282-3415
University of Michigan · USIonis Pharmaceuticals (United States) · USHoward Hughes Medical Institute · USRutgers, The State University of New Jersey · USUniversity of Freiburg · DECleveland State University · USIndiana University Bloomington · USSimon Fraser University · CA

Funding

Tissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ARUL M CHINNAIYAN, Ganesh S Palapattu · 2014 to 2026
$27.6M
CELLULAR AND MOLECULAR BIOLOGY AT MICHIGANT32GM007315 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PUTHENVEEDU, MANOJKUMAR A · 1985 to 2021
$12.8M
Discovery and qualification of transcriptomic biomarkers for the early detection of aggressive prostate cancerU01CA214170 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 2016 to 2021
$3.3M
DETECTION OF CHROMOSOMAL TRANSLOCATIONS BY SINGLE MOLECULE RNA IMAGINGDP5OD012160 · OD · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI BATISH, MONA · 2012 to 2016
$2.1M
NCI NIH HHS P50 CA186786NCI NIH HHS U01 CA214170NIGMS NIH HHS T32 GM007315NIH HHS DP5 OD012160
6 · The paper itself

Abstract

The androgen receptor (AR) plays a critical role in the development of the normal prostate as well as prostate cancer. Using an integrative transcriptomic analysis of prostate cancer cell lines and tissues, we identified ARLNC1 (AR-regulated long noncoding RNA 1) as an important long noncoding RNA that is strongly associated with AR signaling in prostate cancer progression. Not only was ARLNC1 induced by the AR protein, but ARLNC1 stabilized the AR transcript via RNA-RNA interaction. ARLNC1 knockdown suppressed AR expression, global AR signaling and prostate cancer growth in vitro and in vivo. Taken together, these data support a role for ARLNC1 in maintaining a positive feedback loop that potentiates AR signaling during prostate cancer progression and identify ARLNC1 as a novel therapeutic target.

Indexed as

AndrogensCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticHumansMaleProstateProstatic NeoplasmsReceptors, AndrogenRNA, Long NoncodingSignal TransductionAndrogensAR protein, humanReceptors, AndrogenRNA, Long Noncoding

Identifiers

PMID29808028
PMCPMC5980762
OpenAlexW2803499181

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.